---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014819"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:49:39.197886+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma receives FDA Fast Track designation for norovirus antiviral CDI-988

## Summary
- FDA granted Fast Track designation for oral, direct-acting protease inhibitor CDI-988 for norovirus.
- CDI-988 is first oral antiviral candidate for both treatment and prophylaxis of norovirus infection.
- Phase 1b double-blind challenge study (NCT07198139) ongoing at Emory University in up to 40 adults.
- Norovirus causes ~685M global infections/year with ~$60B worldwide economic impact.
- Fast Track enables rolling NDA review and potential Priority Review; no financial terms disclosed.

## SEC filing metadata
- accession: 0001493152-26-014819
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226014819/0001493152-26-014819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226014819/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014819
- JSON: https://secwatch.observer/filing/0001493152-26-014819.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.